Iterion Therapeutics - previously dba Beta Cat Pharmaceuticals - is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The companyâs lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and other solid tumor types. The Company has been enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors
